super tuesday[lament to follow]

Posted on Tuesday 13 March 2012

Journal of Child and Adolescent Psychopharmacology

Special Issue on Psychopharmacology of Adolescent Depression
Guest Editor: G.J. Emslie, MD
FREE ISSUE

Editorial
Guest Editorial
Original Articles
  1.  
    March 13, 2012 | 8:21 PM
     

    Often free issues are sponsored by pharma. Who’s the sponsor of this one?

  2.  
    March 13, 2012 | 9:20 PM
     

    Oh, pharma is represented alright, with some of their favorite KOL’s

    Co- author of PAXIL 329 (wagner), Martin Keller, Koplewicz (of the adhd ‘ransom notes ad campaign fame) and Gabrielle Carlson:

    The AACAP 2009 January Psychopharmacology Update Institute faculty includes:

    Gabrielle A. Carlson, M.D.

    Advisor/Consultant: Bristol-Myers Squibb Company, Eli Lilly and Company, Otsuka America Pharmaceutical, Inc., Validus

    Honorarium and Travel Expenses: American Academy of Child & Adolescent Psychiatry, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc.

    Research Funding: Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Otsuka America Pharmaceutical, Inc.

    Spouse Advisor/Consultant: Eli Lilly and Company, H. Lundbeck A/S
    ——
    It’s always tainted isn’t it. Maybe we should start a card collector’s game with KOL’s on the cards, who should be the number card to attain? Biederman? Nemeroff? so much competition!

  3.  
    March 13, 2012 | 10:22 PM
     

    I saw a psychiatric nurse describe a man as “resisting” and “uncooperative” because no matter how many times she repeated herself, he did not understand English. He was gentle as a baby deer. For some reason the nurse needed to see him as a threat.

    “Problems with authority” works both ways. I blanch to think about these “free” articles being used by mental health professionals in State and County institutions to justify the drugging of children and teenagers to make them suffer quietly and to internalize blame for their failure to be happy and compliant with authority figures who don’t have time to treat them as anything other than “problems” like “treatment resistant depression”.

  4.  
    Angus
    March 14, 2012 | 4:33 AM
     

    I don’t know whether you have already seen this article from Plos Medicine, but thought it might be of interest:

    A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations with Industry: A Pernicious Problem Persists

    http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001190

  5.  
    Talbot
    March 14, 2012 | 7:17 AM
     

    If there’s anything you’ve shown us, it’s that different studies of the same subject can have varying results, and that there can be a fair amount of chicanery in how they are analyzed, presented, and supported.

    A fast look at any of these articles shows a good reason not to pay any attention–the number of citations that make a global claim based on a single study. This is a basic of hack work, but belongs nowhere in a respectable medical journal.

    This thing was bought and paid for.

Sorry, the comment form is closed at this time.